Research programme: ligand-conjugated antisense-based therapeutics - Ionis Pharmaceuticals

Drug Profile

Research programme: ligand-conjugated antisense-based therapeutics - Ionis Pharmaceuticals

Alternative Names: ISIS TMPR SS6 LRx; ISIS-ANGPTL3LRx

Latest Information Update: 24 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action ANGPTL3 protein inhibitors; Apolipoprotein A inhibitors; Apolipoprotein C-III inhibitors; RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Beta-thalassaemia; Dyslipidaemias; Hyperlipoproteinaemias; Hypertriglyceridaemia; Resistant hypertension

Most Recent Events

  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 31 Dec 2014 Isis Pharmaceutical has a US patent protection (US patent no. 7 598 227) for methods of treating hyperlipidemia, lowering cholesterol and triglyceride levels with an antisense oligonucleotide hybridised within nucleotides of apolipoprotein C III (Isis Pharmaceuticals 10-K, April 2015)
  • 31 Dec 2014 Isis Pharmaceuticals has patent protection (US patent no. 7 101 993) for 2'-O-(2-methoxy) ethyl modified nucleosides (Isis pharmaceuticals 10-K, April 2015).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top